All News
Implantable vagal stimulator led to benefit in TNF-inadequate responder RA in this sham-controlled double-blind RCT (RESET-RA study)
- 82% off b/tsDMARDs at 12mo
- also with benefit to control group after crossover at 3mo to an active device
#ACR25 1675 @RheumNow https://t.co/yYwWCKm6HF
David Liew drdavidliew ( View Tweet)
Did we need a 2nd Interception RCT of HCQ in Pre-RA?
Unsure but in any case, it does not work either
STOPRA CCP3+>=2 ind 71 HCQ and 74 PBO
36 months RA conversion
Dr Deane's take: "probably wrong drug rather than wrong timing"
#ACR25 @RheumNow #ABSTRACT1674 https://t.co/jysdo8iz7v
Aurelie Najm AurelieRheumo ( View Tweet)
#ACR25 SMILE RCT of Incomplete #SLE (ANA+ but not meeting SLICC) showed HCQ didn’t slow down SLE progression. But multiplex arrays showed reduction in autoantibodies with HCQ that were distinct from abs assoc. w progression. Would biomarker endpoints be the answer? @RheumNow https://t.co/XcvacgObVo
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
In a cohort of 269,304 IBD patients, NSAID use showed a small increase in IBD-related hospitalisation (HR 1.08), meeting non-inferiority threshold (HR <1.2). No risk in UC (HR 0.96); modest risk in Crohn’s (HR 1.16). Relooks at the current paradigm of blanket NSAID avoidance in https://t.co/O8MWg1BP50
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
56 pts w/tracheobronchial stenosis in GPA, highly frustrating disease manifestation
Not surprising to see severe dx & prior intralesional tx assoc with incidence (ie necessity) of tracheal dilation
Leflunomide protective? Have others seen this?
#ACR @RheumNow Abstr#1596 https://t.co/djJXnAkxnv
Mike Putman EBRheum ( View Tweet)
Sun et al. Telitacicept in SARD-ILD (pSS, ASS, RA). 25 patients. Improvements in CT, PFTs, 6MWT. @RheumNow #ACR25 Abstr#1361 https://t.co/q679LOaOyL
Richard Conway RichardPAConway ( View Tweet)
In pooled analysis of 9 PsA trials, 6.9% of secukinumab-treated patients had fungal infections, mostly mild/moderate. Candida rates were low (1.86–2.18/100 PY) and didn’t increase over time. 89.7% resolved fully; only 0.8% led to discontinuation. Abstract 1459 @RheumNow #ACR25 https://t.co/kltMZVEDf9
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
England et al. Predictors of progression RA-ILD - UIP pattern (HR 1.46), current (HR 1.98) and former (HR 1.60) smoking, age (HR 1.03). @RheumNow #ACR25 Abstr#1308 https://t.co/IvQo8Istta
Richard Conway RichardPAConway ( View Tweet)
Interim analysis of Ph3 TULIP-SC trial:
Anifrolumab 120mg SC or PBO weekly + SOC x 52wks
Primary endpt met: BICLA response w/Anifrolumab (60.3%) vs. PBO(43.9%)[p=0.014]
Pts on Ani had sustained BICLA response upto wk 52 (HR 2.1)
Promising results.
#ACR25 @RheumNow Abs1545 https://t.co/nqse1BiGq2
Links:
sheila RHEUMarampa ( View Tweet)
In Sjögren’s, cancer risk is real.
>9yr multicenter cohort (n=314), overall cancer risk ↑ (SIR 1.68), NHL >15× expected
Predictors: older age, smoking, LAD, splenomegaly, cryoglobulinemia (strongest for lymphoma).
Malignancies = 24% of deaths
@RheumNow #ACR25 Abstract #1681
Jiha Lee JihaRheum ( View Tweet)
Pope @Janetbirdope et al. Parenteral (IM and/or IA) superior to oral steroids in early RA. Better discontinuation of steroids with no difference in need for advanced therapies. @RheumNow #ACR25 Abstr#1355 #ACRbest https://t.co/OyvnzEGlLE
Richard Conway RichardPAConway ( View Tweet)
In a prespecified exploratory analysis of REGENCY trial data by DrRovin et al,
Bet. wks 24 and 76:
Obinutuzumab ⬇️ LN flares vs. PBO (HR 0.44; p=0.0074)
Pts on Obi had less unfavorable kidney outcomes vs. PBO (HR 0.37; p=0.0039)
Addtl tx option for LN
#ACR25 @RheumNow Abs1521 https://t.co/N5K9Nzh71E
sheila RHEUMarampa ( View Tweet)
Post-hoc analysis of CARE(Ph2B) Study to assess sustained responses in mSLEDAI-2K vs. PBO x 12mos in pts given Cenerimod
Sustained response in Cenerimod Ex-4mg (63.5%) > PBO (50%); HR 1.43
Ongoing research, further data needed.
#ACR25 @RheumNow Abs1519 https://t.co/cQbVVIIyxW
sheila RHEUMarampa ( View Tweet)
Infection data from SELECT-GCA:
Glucocorticoids seem to drive overall infectious risk
UPA use associated with higher zoster - vaccinate!!
@RheumNow #ACR25 Abst# 0895 https://t.co/ueVbFPxG0Q
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Prednisone remains both lifeline and liability.
New PRED-SAFE SDM tool helps patients and clinicians navigate that tension—visualizing benefits and harms to guide tapering. In pilot testing, 93% had no residual decisional conflict.
@RheumNow #ACR25 Abstract#1052 #ACRbest https://t.co/CgQ75N7A1p
Jiha Lee JihaRheum ( View Tweet)
Post Hoc analysis from SELECT-GCA
Increased rate of herpes zoster for 26wk steroid-UPA 15mg (7.3% vs 4.2% 52wk steroid-plbo) but lower rate of SERIOUS infections (7.9% vs 12.7% 52wk steroid-plbo)
Zoster risk is real; steroids are the bigger problem
@Rheumnow #ACR25 Abstr#0895 https://t.co/IKzO2J4hLH
Links:
Mike Putman EBRheum ( View Tweet)
Rural RA care looks different but not less intensive: DMARD and GC use matched urban rates, yet rural pts often managed by PCPs had twice the opioid use.
ACR's Rheum for Primary Care resource can help address access gap and improve RA care
@RheumNow #ACR25 Abstract#1025
Jiha Lee JihaRheum ( View Tweet)
Liraglutide had decreased synovial inflammation and fibrosis in mouse models, however dexamethasone didnt have changes in fibrosis scores
Abst#1734 #ACR25 @RheumNow https://t.co/O4JYGtDD5N
Bella Mehta bella_mehta ( View Tweet)
Analysis from FVSG identified 36pts with anti-rituximab antibodies
In AAV, lookout for this in pts who are MPO+ & w/higher CD19 at 6 mos. Worse relapse free survival in both AAV & CRYO!
@TerrierBen can you share the prevalence of these abs?
#ACR25 @RheumNow #ACRBest abstr#1604 https://t.co/Nyx6JxbvUk
Links:
Mike Putman EBRheum ( View Tweet)
A combined biomarker assay may predict which AAV patients will not respond to RTX therapy
A next step towards precision / personalized rheumatology?
@RheumNow #ACR25 Abst 1602 https://t.co/gcrZUNV0b9
Links:
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
